Bayer rethinking plastics IPO plans; WHO's new HIV drug guidelines could boost Gilead, GSK;

@FiercePharma: Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. FiercePharmaMarketing story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Bayer eyes challenge to oral MS meds with new Betaseron injector. Article | Follow @CarlyHFierce

> Bayer and its advisers are rethinking options for the IPO of the company's plastics unit, scheduled for this Friday; books are still not covered, sources told Reuters Wednesday. Report

> The World Health Organization (WHO) is calling for early treatment with anti-retroviral drugs for HIV patients, a push that could give HIV drugmakers like Gilead ($GILD) and GlaxoSmithKline ($GSK) a boost. Report

> Novartis ($NVS) has issued a voluntary recall of an ADHD drug manufactured in Georgia. More

> Pfizer's ($PFE) Wyeth subsidiary will perform nearly $194 million worth of cleanup work at the American Cyanamid Superfund Site in Bridgewater Township, NJ. Report

> The U.S. Patent and Trademark Office (PTO)'s Patent Trial and Appeal Board has, through the inter partes review system, found two patents on Novartis' Exelon Patch to be unpatentable. Release

> Novartis has opened a global data center at its Alcon campus in Fort Worth, TX. More

Medical Device News

@FierceMedDev: Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: MedImmune licenses 3M compound in hopes of developing intratumorally injected cancer drug. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: OraSure reels in $7.2M from HHS for rapid Ebola test. FierceDiagnostics story | Follow @EmilyWFierce

> Baxter makes nice with activist investor Third Point, offers board seats. Report

> Bard to buy out Medicon, its long-standing Japanese JV with Kobayashi. Article

Biotech News

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

@DamianFierce: Here's what it's like to try to get Sovaldi in my home town. More from The Atlantic | Follow @DamianFierce

> Execs behind Imbruvica raise $75M for a new cancer project. News

> Racing AstraZeneca, Clovis gets a speedy FDA review for its lung cancer drug. Story

> Astellas inks a back-loaded $515M deal to get its hands on a pain drug. Article

Biotech Research News

> The contentious gene editing field gets a tech upgrade. What now? Story

> FDA's 'breakthrough' endorsement carries real weight with the public. Report

> Looking for an alternative to pricey Daraprim? You may be in luck. More

> Researchers zero in on immune system's role in Alzheimer's. Story

> A molecule isolated from the depths of the ocean shows promise in treating AML. Article

Diagnostics News

> Diagnostics companies strike back at CMS lab test rule. More

> OraSure reels in $7.2M from HHS for rapid Ebola test. Item

> Dako to develop companion diagnostic for Pfizer and Merck KGaA's joint cancer candidate. Report

> Illumina launches solid tumor sequencing panel aimed at Big Pharma researchers. Story

> Quest launches patient analytics tool for healthcare providers. Article

Pharma Marketing News

> Roche poised for MS coup with success in hard-to-treat progressive form. Article

> Looking for the next wave of pharma innovation? Try opening the door to more partners, Accenture says. More

> Another reason Tresiba uptake is crucial to Novo: Xultophy's blockbuster hopes. Story

> New Hampshire AG puts pain drug marketing under his microscope. Item

> JAMA: 'Breakthrough' talk in FDA press releases could unfairly sway consumers. Report

And Finally... More than 15 million people enrolled in the top 10 Medicare Part D prescription drug plans will face average premium hikes of 8% in 2016, a new analysis says. More

Suggested Articles

AbbVie has seen blossoming market share for immunology launches Rinvoq and Skyrizi—and it's eyeing Allergan's neurology biz for a boost, too.

While Novo's Rybelsus launch has slowed due to the pandemic, another version of the med, Ozempic posted strong sales.

AZ sold Atacand and Atacand Plus rights in about 70 countries to Cheplapharm.